Alan L. Rubino has been appointed president and chief executive officer of Emisphere Technologies, Inc. Mr. Rubino was also elected to the board of directors.
 
Mr. Rubino has more than 30 years of biopharmaceutical industry experience. Most recently, he served as chief executive officer and president of New American Therapeutics, where he and his team led the acquisition, marketing, and ultimate sale of Denavir, a topical treatment for HSV-1 cold sores. Mr. Rubino's career includes 24 years with Hoffmann-La Roche, where he became a corporate officer and member of the U.S. Executive Committee. He held a variety of key senior executive positions with broad general management responsibilities leading major business units and operations, marketing, business development, alliance management, human Resources , and supply chain/manufacturing.
 
"Alan is a seasoned industry executive with major and emerging pharmaceutical company experience. Throughout his career, he has consistently demonstrated the ability to successfully launch and grow profitable pharmaceutical products and efficient businesses. His versatile experiences, extensive industry connections and business development network, and exceptional reputation make him ideally suited to secure Emisphere's commercial success," said Dr. Michael Weiser, a member of Emisphere’s board.
 
Also, Timothy G. Rothwell has been appointed chairman of the board at Emisphere. Mr. Rothwell is the former chairman of Sanofi-Aventis U.S., and served as president and chief executive officer. He held various roles at Sanofi-Aventis U.S., and was responsible for overseeing all domestic commercial operations as well as coordinating Industrial Affairs and R&D activities.